54325 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Jul 31
10:44 UTC
|
MKTX
MarketAxess
|
↓ Downgrade | Alex Kramm ★★★★★ #112 | Buy→ Neutral | $167.00 |
|
Jul 31
10:44 UTC
|
GDDY
GoDaddy
|
↓ Downgrade | firm only | Market Perform | |
|
Jul 31
10:44 UTC
|
NXT
Nextpower
|
↑ Upgrade | Ameet Thakkar ★★★☆☆ #2094 | Market Perform→ Outperform | |
|
Jul 31
10:44 UTC
|
ESS
Essex Property Trust
|
↑ Upgrade | firm only | Buy→ Outperform | |
|
Jul 31
00:43 UTC
|
ZWS
Zurn Elkay Water Solutions Cor
|
◎ Target | Jeffrey Reive not yet tracked | Sec→ r Perform | $56.00→ $58.00+3.6% |
|
Jul 31
00:43 UTC
|
ZWS
Zurn Elkay Water Solutions Cor
|
◎ Target | Nathan Jones ★★★☆☆ #1682 | Buy | $56.00→ $62.00+10.7% |
|
Jul 31
00:43 UTC
|
XYL
Xylem
|
◎ Target | Joshua Spector ★★★☆☆ #1727 | Neutral | $129.00→ $135.00+4.7% |
|
Jul 31
00:43 UTC
|
WSO
Watsco
|
◎ Target | Chris Dankert ★★★☆☆ #1238 | Neutral | $385.00→ $330.00-14.3% |
|
Jul 31
00:43 UTC
|
WPC
W.P. Carey
|
◎ Target | Brad Heffern ★★★★☆ #362 | Sec→ r Perform | $73.00→ $77.00+5.5% |
|
Jul 31
00:43 UTC
|
WM
Waste Management
|
◎ Target | William Grippin ★★★☆☆ #2173 | Overweight | $270.00→ $277.00+2.6% |
|
Jul 31
00:43 UTC
|
WM
Waste Management
|
◎ Target | Shlomo Rosenbaum ★★★★★ #184 | Buy | $252.00→ $261.00+3.6% |
|
Jul 31
00:43 UTC
|
WM
Waste Management
|
◎ Target | Sabahat Khan ★★★☆☆ #1613 | Sec→ r Perform | $240.00→ $244.00+1.7% |
|
Jul 31
00:43 UTC
|
WING
Wingstop
|
◎ Target | Todd Brooks ★★★★☆ #902 | Buy | $285.00→ $245.00-14.0% |
|
Jul 31
00:43 UTC
|
WING
Wingstop
|
◎ Target | Logan Reich ★★★★☆ #970 | Outperform | $225.00→ $200.00-11.1% |
|
Jul 31
00:43 UTC
|
WING
Wingstop
|
◎ Target | Jon Tower ★★★☆☆ #986 | Buy | $237.00→ $208.00-12.2% |
|
Jul 31
00:43 UTC
|
WING
Wingstop
|
◎ Target | Matt Curtis ★★★☆☆ #2103 | Buy | $200.00→ $190.00-5.0% |
|
Jul 31
00:43 UTC
|
WING
Wingstop
|
◎ Target | John Glass not yet tracked | Overweight | $255.00→ $238.00-6.7% |
|
Jul 31
00:43 UTC
|
WING
Wingstop
|
◎ Target | Zachary Fadem ★★★★☆ #960 | Overweight | $170.00→ $165.00-2.9% |
|
Jul 31
00:43 UTC
|
WING
Wingstop
|
◎ Target | Peter Saleh ★★★★☆ #520 | Buy | $305.00→ $265.00-13.1% |
|
Jul 31
00:43 UTC
|
WEIR
The Weir Group
|
◎ Target | firm only | Buy | GBX 3,150→ GBX 3,200+1.6% |
|
Jul 31
00:43 UTC
|
WAY
Waystar
|
◎ Target | Kavin Caliendo not yet tracked | Buy | $37.00→ $33.00-10.8% |
|
Jul 31
00:43 UTC
|
WAY
Waystar
|
◎ Target | Stan Berenshteyn ★★★★★ #317 | Overweight | $36.00→ $33.00-8.3% |
|
Jul 31
00:43 UTC
|
VRT
Vertiv
|
◎ Target | Andrew Kaplowitz ★★★☆☆ #1470 | Buy | $414.00→ $358.00-13.5% |
|
Jul 31
00:43 UTC
|
VRT
Vertiv
|
◎ Target | Deane Dray ★★★☆☆ #1828 | Outperform | $418.00→ $337.00-19.4% |
|
Jul 31
00:43 UTC
|
VRT
Vertiv
|
◎ Target | David Tarantino ★☆☆☆☆ #3029 | Overweight | $360.00→ $325.00-9.7% |
|
Jul 31
00:43 UTC
|
VRSK
Verisk Analytics
|
◎ Target | Jason Haas not yet tracked | Overweight | $240.00→ $260.00+8.3% |
|
Jul 31
00:43 UTC
|
VRSK
Verisk Analytics
|
◎ Target | Alex Kramm ★★★★★ #112 | Neutral | $220.00→ $235.00+6.8% |
|
Jul 31
00:43 UTC
|
VRNS
Varonis Systems
|
◎ Target | Fatima Boolani ★★★★★ #252 | Neutral | $30.00→ $45.00+50.0% |
|
Jul 31
00:43 UTC
|
VMC
Vulcan Materials
|
◎ Target | Anthony Pettinari ★★★☆☆ #1080 | Buy | $355.00→ $350.00-1.4% |
|
Jul 31
00:43 UTC
|
VMC
Vulcan Materials
|
◎ Target | Anthony Codling ★★★☆☆ #1287 | Sec→ r Perform | $293.00→ $300.00+2.4% |
|
Jul 31
00:43 UTC
|
VLTO
Veralto
|
◎ Target | Andrew Kaplowitz ★★★☆☆ #1470 | Neutral | $102.00→ $107.00+4.9% |
|
Jul 31
00:43 UTC
|
VLTO
Veralto
|
◎ Target | William Grippin ★★★☆☆ #2173 | Overweight | $113.00→ $117.00+3.5% |
|
Jul 31
00:43 UTC
|
VLTO
Veralto
|
◎ Target | Joshua Spector ★★★☆☆ #1727 | Neutral | $98.00→ $104.00+6.1% |
|
Jul 31
00:43 UTC
|
VLTO
Veralto
|
◎ Target | Deane Dray ★★★☆☆ #1828 | Sec→ r Perform | $100.00→ $109.00+9.0% |
|
Jul 31
00:43 UTC
|
VLTO
Veralto
|
◎ Target | Nathan Jones ★★★☆☆ #1682 | Buy | $111.00→ $114.00+2.7% |
|
Jul 31
00:43 UTC
|
VKTX
Viking Therapeutics
|
◎ Target | Edward Nash ★★☆☆☆ #2444 | Buy | $107.00→ $114.00+6.5% |
|
Jul 31
00:43 UTC
|
VFC
V.F.
|
◎ Target | Peter McGoldrick ★★★★☆ #900 | Hold | $19.00→ $17.00-10.5% |
|
Jul 31
00:43 UTC
|
VFC
V.F.
|
◎ Target | Jay Sole ★★★☆☆ #1505 | Neutral | $18.00→ $16.00-11.1% |
|
Jul 31
00:43 UTC
|
VFC
V.F.
|
◎ Target | Adrienne Yih ★★★☆☆ #1564 | Overweight | $24.00→ $23.00-4.2% |
|
Jul 31
00:43 UTC
|
VFC
V.F.
|
◎ Target | Brooke Roach ★★★☆☆ #1920 | Neutral | $18.00→ $16.00-11.1% |
|
Jul 31
00:43 UTC
|
VFC
V.F.
|
◎ Target | Joseph Civello ★★★☆☆ #1869 | Hold | $15.00→ $14.00-6.7% |
|
Jul 31
00:43 UTC
|
VFC
V.F.
|
◎ Target | Ike Boruchow ★★★★☆ #712 | Equal Weight | $18.00→ $16.00-11.1% |
|
Jul 31
00:43 UTC
|
VFC
V.F.
|
◎ Target | firm only | Market Perform | $20.00→ $17.00-15.0% |
|
Jul 31
00:43 UTC
|
VANQ
Vanquis Banking Group
|
◎ Target | firm only | Buy | GBX 165→ GBX 145-12.1% |
|
Jul 31
00:43 UTC
|
VALT
Valt Technology Services
|
◎ Target | firm only | Buy | GBX 7,500→ GBX 7,700+2.7% |
|
Jul 31
00:43 UTC
|
UNM
Unum Group
|
◎ Target | Ryan Krueger ★★★★★ #272 | Outperform | $110.00→ $108.00-1.8% |
|
Jul 31
00:43 UTC
|
UMBF
UMB Financial
|
◎ Target | Christopher McGratty ★★★★☆ #394 | Outperform | $155.00→ $160.00+3.2% |
|
Jul 31
00:43 UTC
|
UIS
Unisys
|
◎ Target | Mayank Tandon ★★★★☆ #398 | Buy | $6.00→ $5.00-16.7% |
|
Jul 31
00:43 UTC
|
UHS
Universal Health Services
|
◎ Target | Scott Fidel ★★★★☆ #510 | Neutral | $242.00→ $190.00-21.5% |
|
Jul 31
00:43 UTC
|
TVTX
Travere Therapeutics
|
◎ Target | Edward Nash ★★☆☆☆ #2444 | Buy | $56.00→ $62.00+10.7% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.